id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC12144160 | core_pubmed_pmc | Computational discovery of novel aryl hydrocarbon receptor modulators for psoriasis therapy | Computational discovery of novel aryl hydrocarbon receptor modulators for psoriasis therapy Abstract Abstract The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor involved in the regulation of many pathophysiological processes. Among these, immune system modulation, as well as regulation of sk... |
PMC4940708 | core_pubmed_pmc | Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease | Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease Abstract Alzheimer’s disease (AD) is an incurable and debilitating chronic progressive neurodegenerative disorder which is the leading cause of dementia worldwide. AD is a he... |
PMC9320685 | core_pubmed_pmc | Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK Model | Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK Model Abstract Physiologically based pharmacokinetic and absorption modeling are being used by industry and regulatory bodies to address various scientifical... |
PMC6771222 | core_pubmed_pmc | A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study | A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study Abstract Abstract Background Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant... |
PMC7770183 | core_pubmed_pmc | Enhanced Bioavailability of Boswellic Acid by Piper longum : A Computational and Pharmacokinetic Study | Enhanced Bioavailability of Boswellic Acid by Piper longum : A Computational and Pharmacokinetic Study Abstract Chronic inflammation is a key culprit factor in the onset and progression of several diseases. Novel and pharmacologically effective therapeutic approaches are needed for new treatment remedy or improved phar... |
PMC4592188 | core_pubmed_pmc | Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations | Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations Abstract Abstract Interindividual variability in anatomical and physiological properties results in significant differences in drug... |
PMC7033599 | core_pubmed_pmc | Resistance Evolution Against Antimicrobial Peptides in Staphylococcus aureus Alters Pharmacodynamics Beyond the MIC | Resistance Evolution Against Antimicrobial Peptides in Staphylococcus aureus Alters Pharmacodynamics Beyond the MIC Abstract Abstract Antimicrobial peptides (AMPs) have been proposed as a promising class of new antimicrobials partly because they are less susceptible to bacterial resistance evolution. This is possibly c... |
PMC8885938 | core_pubmed_pmc | Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope | Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope Abstract Background Vasovagal syncope is a common cause of syncope which, if recurrent, can have multiple negative consequences such as injury and occupational disability. Various medications can be used to... |
PMC12245000 | core_pubmed_pmc | Intravitreal Administration of Adalimumab‐Loaded Poly(Lactic‐co‐Glycolic Acid) Nanoparticles: Effects on Biodistribution and Pharmacokinetics | Intravitreal Administration of Adalimumab‐Loaded Poly(Lactic‐co‐Glycolic Acid) Nanoparticles: Effects on Biodistribution and Pharmacokinetics Abstract Adalimumab, a monoclonal antibody used for treating inflammatory diseases, including eye diseases, faces challenges in biodistribution and targeted delivery. Nanoparticl... |
PMC2825345 | core_pubmed_pmc | Combining the in vivo comet and micronucleus assays: a practical approach to genotoxicity testing and data interpretation | Combining the in vivo comet and micronucleus assays: a practical approach to genotoxicity testing and data interpretation Abstract Abstract Despite regulatory directives requiring the reduction of animal use in safety testing, recent modifications to genotoxicity testing guidelines now propose the use of two in vivo ge... |
PMC6010978 | core_pubmed_pmc | Response to Single Low-dose 177 Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study | Response to Single Low-dose 177 Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study Abstract Abstract Objective: 177 Lu-DOTA-EB-TATE is a theranostic agent based on octreotate that uses an Evans blue structure to bind albumin to improve the pharmacokinetics and pharmac... |
PMC9850716 | core_pubmed_pmc | A Multifaceted Review of Eurycoma longifolia Nutraceutical Bioactives: Production, Extraction, and Analysis in Drugs and Biofluids | A Multifaceted Review of Eurycoma longifolia Nutraceutical Bioactives: Production, Extraction, and Analysis in Drugs and Biofluids Abstract Eurycoma longifolia Jack (known as Tongkat Ali) is a popular traditional herbal medicine, native to southeast Asia, that is well-known for its aphrodisiac as well as several other ... |
PMC5560554 | core_pubmed_pmc | Targeting of CDK9 with indirubin 3’-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice | Targeting of CDK9 with indirubin 3’-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice Abstract Abstract Successful propagation of HIV in the human host requires entry into a permissive cell, reverse transcription of viral RNA, integration into the human genome, transcription of the ... |
PMC8841494 | core_pubmed_pmc | Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials | Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials Abstract Abstract Itepekimab is a monoclonal antibody that targets interleukin (IL‐33) and has been shown to reduce airway inflammation and associated tissue damage in precl... |
PMC4153963 | core_pubmed_pmc | Effect of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Omeprazole Plasma Pharmacokinetics in Healthy Adults | Effect of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Omeprazole Plasma Pharmacokinetics in Healthy Adults Abstract Abstract Background Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid ethyl ester approved by the US Food and Drug Administration as an adjunct to diet to reduce... |
PMC4139609 | core_pubmed_pmc | A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters | A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters Abstract Abstract Background Plantago ovata husk therapy could be used in patients with Parkinson disease to reduce the symptoms of gastrointestinal disorders... |
PMC8596416 | core_pubmed_pmc | Pharmacokinetics and Use‐Testing of Apalutamide Prepared in Aqueous Food Vehicles for Alternative Administration | Pharmacokinetics and Use‐Testing of Apalutamide Prepared in Aqueous Food Vehicles for Alternative Administration Abstract Abstract Patients may have difficulty swallowing a whole daily dose of 240 mg (4 × 60‐mg tablets) of apalutamide. One of the unique properties of apalutamide tablets is easy disintegration and dispe... |
PMC10569676 | core_pubmed_pmc | Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections | Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections Abstract Objectives: To explore the relationship between real-time therapeutic ... |
PMC12107630 | core_pubmed_pmc | Impact of CYP3A5 1* and 3* single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patients | Impact of CYP3A5 1* and 3* single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patients Abstract Tacrolimus, a calcineurin inhibitor, is widely used to prevent allograft rejection in kidney transplant recipients. Its metabolism is predominantly mediated by t... |
PMC9662207 | core_pubmed_pmc | Joint modeling under competing risks: Application to survival prediction in patients admitted in Intensive Care Unit for sepsis with daily Sequential Organ Failure Assessment score assessments | Joint modeling under competing risks: Application to survival prediction in patients admitted in Intensive Care Unit for sepsis with daily Sequential Organ Failure Assessment score assessments Abstract Abstract Joint models of longitudinal process and time‐to‐event data have recently gained attention, notably to provid... |
PMC12914500 | core_pubmed_pmc | Unravelling Voriconazole's Hepatic Metabolism: A Narrative Review on Factors Impacting Voriconazole‐N‐Oxide Exposure | Unravelling Voriconazole's Hepatic Metabolism: A Narrative Review on Factors Impacting Voriconazole‐N‐Oxide Exposure Abstract ABSTRACT Background Voriconazole (VRC), a triazole antifungal agent, is recommended as primary treatment for invasive aspergillosis. Due to its unpredictable dose‐exposure relationship, therapeu... |
PMC10079507 | core_pubmed_pmc | Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects | Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects Abstract Abstract Concomitant administration of lobeglitazone, empagliflozin, and metformin is expected to enhance blood glucose-lowering effects and improve medication compliance in patients with diabetes... |
PMC3112027 | core_pubmed_pmc | Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? | Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? Abstract Purpose Neuroblastoma is the most common extracranial solid tumour in childhood. It accounts for 15% of all paediatric oncology deaths. In the last few decades, improvement in treatment outcome for high-risk pa... |
PMC10498806 | core_pubmed_pmc | Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies | Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies Abstract ABSTRACT Biologic drug discovery pipelines are designed to deliver protein therapeutics that have exquisite functional potency and selecti... |
PMC10571049 | core_pubmed_pmc | Cannabidiol plasma determination and pharmacokinetics conducted at beginning, middle and end of long-term supplementation of a broad-spectrum hemp oil to healthy adult dogs | Cannabidiol plasma determination and pharmacokinetics conducted at beginning, middle and end of long-term supplementation of a broad-spectrum hemp oil to healthy adult dogs Abstract Abstract Introduction Veterinary hemp products containing cannabidiol (CBD) and negligible psychoactive (THC) have increased popularity si... |
PMC8468767 | core_pubmed_pmc | Optimisation of a Microfluidic Method for the Delivery of a Small Peptide | Optimisation of a Microfluidic Method for the Delivery of a Small Peptide Abstract Abstract Peptides hold promise as therapeutics, as they have high bioactivity and specificity, good aqueous solubility, and low toxicity. However, they typically suffer from short circulation half-lives in the body. To address this issue... |
PMC8451790 | core_pubmed_pmc | Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants | Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants Abstract Abstract Gastroparesis is a chronic neuromuscular disorder of the upper gastrointe... |
PMC6058267 | core_pubmed_pmc | The impact of body weight on rivaroxaban pharmacokinetics | The impact of body weight on rivaroxaban pharmacokinetics Abstract Abstract Essentials The optimal dosing strategy of rivaroxaban for patients at the extremes of body weight is not known. A pharmacokinetic study was conducted based in real‐world patients in a London teaching hospital. In the cohort of patients studied,... |
PMC10537618 | core_pubmed_pmc | Effect of Betanin, the Major Pigment of Red Beetroot ( Beta vulgaris L.), on the Activity of Recombinant Human Cytochrome P450 Enzymes | Effect of Betanin, the Major Pigment of Red Beetroot ( Beta vulgaris L.), on the Activity of Recombinant Human Cytochrome P450 Enzymes Abstract Most of the currently available drugs are derived from natural sources, but they are used only after extensive chemical modifications to improve their safety and efficacy. Natu... |
PMC9698634 | core_pubmed_pmc | A Physiologically Based Pharmacokinetic (PBPK) Modeling Framework for Mixtures of Dioxin-like Compounds | A Physiologically Based Pharmacokinetic (PBPK) Modeling Framework for Mixtures of Dioxin-like Compounds Abstract Humans are exposed to persistent organic pollutants, such as dioxin-like compounds (DLCs), as mixtures. Understanding and predicting the toxicokinetics and thus internal burden of major constituents of a DLC... |
PMC5404337 | core_pubmed_pmc | Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study | Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study Abstract Abstract Background Cisplatin is a high-potency anticancer agent; however, it causes significant adverse drug reactions (ADRs). Potent... |
PMC5541360 | core_pubmed_pmc | Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study | Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study Abstract Introduction The most common classification of acute myocardial infarction (AMI) is based on electrocardiographic findings and distinguishes ST-... |
PMC5628680 | core_pubmed_pmc | In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts | In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts Abstract Epidermal growth factor receptor (EGFR), upregulated in gastric cancer patients, is an oncogene of interest in the development of targeted cancer nanomedicines. This study d... |
PMC12931727 | core_pubmed_pmc | Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection | Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection Abstract ABSTRACT Live microbiota therapies have shown promise in many gastrointestinal diseases, including in the prevention of recurrent Clostridioides difficile i... |
PMC3675106 | core_pubmed_pmc | Vincristine Chemotherapy Trials and Pharmacokinetics in Tasmanian Devils with Tasmanian Devil Facial Tumor Disease | Vincristine Chemotherapy Trials and Pharmacokinetics in Tasmanian Devils with Tasmanian Devil Facial Tumor Disease Abstract Tasmanian Devil Facial Tumor Disease (DFTD) is a transmissible cancer threatening to cause the extinction of Tasmanian Devils in the wild. The aim of this study was to determine the susceptibility... |
PMC11511931 | core_pubmed_pmc | The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials | The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials Abstract Regulatory T cell (Treg) impairment is implicated in the pathogenesis of chronic inflammatory diseases, but relativel... |
PMC2841147 | core_pubmed_pmc | The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma | The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma Abstract Abstract GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects. We evaluated the effects of GSK256066 on airway responses to allergen ch... |
PMC9695338 | core_pubmed_pmc | Influences of Glimepiride Self-Nanoemulsifying Drug Delivery System Loaded Liquisolid Tablets on the Hypoglycemic Activity and Pancreatic Histopathological Changes in Streptozotocin-Induced Hyperglycemic Rats | Influences of Glimepiride Self-Nanoemulsifying Drug Delivery System Loaded Liquisolid Tablets on the Hypoglycemic Activity and Pancreatic Histopathological Changes in Streptozotocin-Induced Hyperglycemic Rats Abstract The development of an oral anti-diabetic medication characterized by enhanced hypoglycemic activity is... |
PMC3469239 | core_pubmed_pmc | Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: A literature review comparing amlodipine and nifedipine GITS | Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: A literature review comparing amlodipine and nifedipine GITS Abstract Calcium-channel blockers (CCBs) constitute a diverse group of compounds but are often referred to as a single homogeneous class of drug and ... |
PMC3558400 | core_pubmed_pmc | P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines | P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines Abstract Abstract Background Mantle cell lymphoma (MCL) is a well-defined aggressive lymphoid neoplasm characterized by proliferation of mature B-lymphocytes that have a remar... |
PMC3232196 | core_pubmed_pmc | Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients | Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients Abstract Abstract Background Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based antiviral therapy and anti-tubercula... |
PMC6824394 | core_pubmed_pmc | Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study | Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study Abstract Abstract Introduction Oxycodone ARIR is a novel oral, abuse-deterrent, immediate-release (IR) formulation with physical and chemical properties that deter misuse and abuse by no... |
PMC11525524 | core_pubmed_pmc | Exploring Thermal Stability, Vibrational Properties, and Biological Assessments of Dichloro( l -histidine)copper(II): A Combined Theoretical and Experimental Study | Exploring Thermal Stability, Vibrational Properties, and Biological Assessments of Dichloro( l -histidine)copper(II): A Combined Theoretical and Experimental Study Abstract Abstract Dichloro( l -histidine)copper(II) crystal ([Cu( l -His)Cl 2 ] complex) was obtained by the slow evaporation method and characterized conce... |
PMC9229894 | core_pubmed_pmc | In Silico, In Vitro, and Pharmacokinetic Studies of UBMC-4, a Potential Novel Compound for Treating against Trypanosoma cruzi | In Silico, In Vitro, and Pharmacokinetic Studies of UBMC-4, a Potential Novel Compound for Treating against Trypanosoma cruzi Abstract Abstract The lack of therapeutic alternatives for the treatment of Chagas disease, a neglected disease, drives the discovery of new drugs with trypanocidal activity. Consequently, we co... |
PMC12202829 | core_pubmed_pmc | Cardiovascular and Pharmacokinetic Profiles of Intravenous Etripamil in Conscious Telemetered Cynomolgus Monkeys | Cardiovascular and Pharmacokinetic Profiles of Intravenous Etripamil in Conscious Telemetered Cynomolgus Monkeys Abstract Paroxysmal supraventricular tachycardia (PSVT) is a common cardiac arrhythmia associated with substantial health care burden. Etripamil, a fast-acting non-dihydropyridine calcium channel blocker dev... |
PMC12640667 | core_pubmed_pmc | Potent Antisickling Furaldehyde Analogs for Acute Sickle Cell Therapy: Enhanced Efficacy and Intravenous Formulation Potential | Potent Antisickling Furaldehyde Analogs for Acute Sickle Cell Therapy: Enhanced Efficacy and Intravenous Formulation Potential Abstract Sickle cell disease (SCD) is a debilitating inherited blood disorder characterized by acute crises that require immediate intervention. Aromatic aldehydes that increase hemoglobin (Hb)... |
PMC10870265 | core_pubmed_pmc | Oral Release Kinetics, Biodistribution, and Excretion of Dopants from Barium-Containing Bioactive Glass in Rats | Oral Release Kinetics, Biodistribution, and Excretion of Dopants from Barium-Containing Bioactive Glass in Rats Abstract Background : Inorganic biomaterials are biologically active and are used as implants and drug delivery system. They have therapeutically active elements present in their framework that are released i... |
PMC6394163 | core_pubmed_pmc | Development and Validation of Liquid Chromatography Method for Determination of Glimepiride in Presence of (Vimto ® ) Soft Drinks in Rats: Application to Pharmacokinetics Studies. | Development and Validation of Liquid Chromatography Method for Determination of Glimepiride in Presence of (Vimto ® ) Soft Drinks in Rats: Application to Pharmacokinetics Studies. Abstract Abstract Context: Diet and beverages are thought to have notable effects on drugs. Recently, this relationship has received signifi... |
PMC7350388 | core_pubmed_pmc | The PK/PD Integration and Resistance of Tilmicosin against Mycoplasma hyopneumoniae | The PK/PD Integration and Resistance of Tilmicosin against Mycoplasma hyopneumoniae Abstract Mycoplasma hyopneumoniae is the major pathogen causing enzootic pneumonia in pigs. M. hyopneumoniae infection can lead to considerable economic losses in the pig-breeding industry. Here, this study established a first-order abs... |
PMC7109127 | core_pubmed_pmc | A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma | A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma Abstract Background Hepatocellular carcinoma (HCC) is a major cause of cancer-related death. It is a highly vascular tumour with multiple angiogenic factors, most importantly vascular endothelial growth factor (VEG... |
PMC8478771 | core_pubmed_pmc | Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data | Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data Abstract Immunosuppressive drugs can alleviate debilitating symptoms of autoimm... |
PMC9314093 | core_pubmed_pmc | Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment | Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment Abstract Abstract Aim This phase I study investigated talazoparib pharmacokinetics (PK) and safety in patients with advanced solid tumours and varying degrees of hepatic function. Methods ... |
PMC12301304 | core_pubmed_pmc | Potential induction of the relative mRNA expression levels of CYP450 by Zhicaowu-Hezi (Aconiti kusnezoffii radix preparata and Terminalia chebula Retz.) | Potential induction of the relative mRNA expression levels of CYP450 by Zhicaowu-Hezi (Aconiti kusnezoffii radix preparata and Terminalia chebula Retz.) Abstract Abstract Background Processed Aconiti Kusnezoffii Radix (Aconiti kusnezoffii Radix Preparata, Zhicaowu) and Terminalia chebula Retz. (Hezi) are a classic herb... |
PMC10955104 | core_pubmed_pmc | Recent advances in carbon monoxide-releasing nanomaterials ☆ | Recent advances in carbon monoxide-releasing nanomaterials ☆ Abstract As an endogenous signaling molecule, carbon monoxide (CO) has emerged as an increasingly promising option regarding as gas therapy due to its positive pharmacological effects in various diseases. Owing to the gaseous nature and potential toxicity, it... |
PMC5554291 | core_pubmed_pmc | Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan | Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan Abstract Abstract Introduction Percutaneous hepatic perfusion (PHP) with melphalan is an effective treatment for patients with h... |
PMC10620120 | core_pubmed_pmc | Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers | Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers Abstract Targeted therapies for prostate, breast, and ovarian cancers are based on their activity against primary tumors rather than their anti‐metastatic activity. Consequently, there is an urgent need for new agents targeting the ... |
PMC11762134 | core_pubmed_pmc | Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022) | Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022) Abstract Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrob... |
PMC9542796 | core_pubmed_pmc | Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach | Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach Abstract Abstract Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report a mod... |
PMC12566952 | core_pubmed_pmc | Virtual Bioequivalence Assessment and Dissolution Safe Space Exploration for Fixed-Dose Metformin–Glyburide Tablet Using Physiologically Based Biopharmaceutics Modeling | Virtual Bioequivalence Assessment and Dissolution Safe Space Exploration for Fixed-Dose Metformin–Glyburide Tablet Using Physiologically Based Biopharmaceutics Modeling Abstract Abstract Background/Objectives : Fixed-dose combinations (FDCs) hold significant clinical value for the management of hypertension, diabetes a... |
PMC12165324 | core_pubmed_pmc | Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor | Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor Abstract ABSTRACT Epaminurad, a novel uricosuric agent, exhibits potent inhibitory activity against the human uric acid transporter. This study aimed to investigate the effects of rena... |
PMC12638730 | core_pubmed_pmc | Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment | Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment Abstract Abstract Aim: To determine effects of Coenzyme Q10 (CoQ10) supplementation in breast cancer patients receiving doxorubicin treatment. Methods: Phase I randomized,... |
PMC4767723 | core_pubmed_pmc | Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies | Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies Abstract Abstract Background and objectives Fostamatinib is a spleen tyrosine kinase inhibitor that has been investigated as therapy for rheumatoid arthrit... |
PMC8545549 | core_pubmed_pmc | Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy | Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy Abstract Abstract Paclitaxel is a broad-spectrum anticancer compound, which was derived mainly from a medicinal plant, in particular, from the bark of the yew tree Taxus brevifolia Nutt. It is a representative of a class of diterpene taxan... |
PMC11843794 | core_pubmed_pmc | Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis | Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis Abstract Background: Delirium is a severe neuropsychiatric disorder associated with increased morbidity and mortality. Numerous precipitating factors and etiologies merge into the pat... |
PMC7506777 | core_pubmed_pmc | Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections | Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections Abstract Abstract Introduction: The information about the pharmacokinetics and optimal dose of tigecycline in critically ill patients with severe und... |
PMC12114997 | core_pubmed_pmc | Risk of Potentially Neurotoxic Exposure in Infants Under High-Dose Cefepime Treatment—A Pharmacometric Simulation Study | Risk of Potentially Neurotoxic Exposure in Infants Under High-Dose Cefepime Treatment—A Pharmacometric Simulation Study Abstract Background: Optimal dosing of cefepime in infants 1–2 months remains undefined. Objectives : We aimed to quantify the risk of potentially neurotoxic exposure with high-dose cefepime (50 mg/kg... |
PMC12297938 | core_pubmed_pmc | Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity | Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity Abstract Abstract Background : Olanzapine (Ola) is a second-generation antipsychotic with clinical utility limited by poor brain bioavailability due to blood–brain barrier restriction, hepatic fir... |
PMC3104459 | core_pubmed_pmc | Teicoplanin Dosing Strategy for Treatment of Staphylococcus aureus in Korean Patients with Neutropenic Fever | Teicoplanin Dosing Strategy for Treatment of Staphylococcus aureus in Korean Patients with Neutropenic Fever Abstract Abstract Purpose The present study was conducted to determine and compare the target attainment rate (TAR) between microorganism-nonspecific (C trough ) and microorganism-specific (AUC 24 /MIC) targets ... |
PMC12468763 | core_pubmed_pmc | New chalcone compound exhibits microrna-mediated anticancer properties in glioblastoma | New chalcone compound exhibits microrna-mediated anticancer properties in glioblastoma Abstract Abstract Background Therapy-resistant glioblastoma constitutes the most lethal adult brain malignancy, bearing extremely poor patients’ prognosis. Combinational therapies are accompanied by severe side effects and significan... |
PMC7541708 | core_pubmed_pmc | First‐in‐Human Studies of MW01‐6‐189WH, a Brain‐Penetrant, Antineuroinflammatory Small‐Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers | First‐in‐Human Studies of MW01‐6‐189WH, a Brain‐Penetrant, Antineuroinflammatory Small‐Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers Abstract Abstract MW01‐6‐189WH (MW189) is a novel central nervous system–penetrant small‐molecule drug ca... |
PMC10675244 | core_pubmed_pmc | A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients | A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients Abstract Tacrolimus is the principal immunosuppressive drug which is administered after heart transplantation. Managing tacrolimus therapy is challenging due to a narrow therapeutic index ... |
PMC5057311 | core_pubmed_pmc | Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals | Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals Abstract Background Receptor occupancy (RO) assays measure drug target engagement, and are used as pharmacodynamic (PD) biomarkers. RO assays are commonly performed by flow cytometry and often require multiple... |
PMC4700386 | core_pubmed_pmc | Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial | Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial Abstract Summary Background Artefenomel (OZ439) is a novel synthetic trioxolane with improved pharmacokinetic properties compared wi... |
PMC12478331 | core_pubmed_pmc | Spatial‐hindrance‐based pro‐Adalimumab prevents anti‐idiotypic antibody interference in pharmacokinetic and therapeutic efficacy | Spatial‐hindrance‐based pro‐Adalimumab prevents anti‐idiotypic antibody interference in pharmacokinetic and therapeutic efficacy Abstract Abstract Adalimumab (Humira) represents a major advance in rheumatoid arthritis (RA) therapy. However, with long‐term administration of Adalimumab, anti‐idiotypic antibody (anti‐Id A... |
PMC8241153 | core_pubmed_pmc | Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab -paclitaxel | Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab -paclitaxel Abstract Abstract Angiogenesis is critical to the growth of tumors. Vascularization-targeting agents, with or without cytotoxic drugs, are widely used for the treatment of several solid tumors including esoph... |
PMC7160569 | core_pubmed_pmc | Computational studies of a series of 2-substituted phenyl-2-oxo-, 2-hydroxyl- and 2-acylloxyethylsulfonamides as potent anti-fungal agents | Computational studies of a series of 2-substituted phenyl-2-oxo-, 2-hydroxyl- and 2-acylloxyethylsulfonamides as potent anti-fungal agents Abstract Botrytis Cinerea is a plant pathogen that affect a large number of plant species like tomatoes, Lettuce, Grapes, and Strawberries among others. Sulfonamides are widely used... |
PMC11597902 | core_pubmed_pmc | Potential Protective Effect of Orlistat: A Formulation of Nanocrystals Targeting Inflammation, Oxidative Stress, and Apoptosis in an Experimental Model of Doxorubicin-Induced Cardiotoxicity | Potential Protective Effect of Orlistat: A Formulation of Nanocrystals Targeting Inflammation, Oxidative Stress, and Apoptosis in an Experimental Model of Doxorubicin-Induced Cardiotoxicity Abstract Background : Doxorubicin (DOX) is a widely used chemotherapeutic agent; nevertheless, cardiotoxicity limits its effective... |
PMC9531608 | core_pubmed_pmc | Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 Years | Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 Years Abstract Background This prospective, open-label trial was conducted to fulfil a post-approval commitment made to the competent authorities to extend the indication of the strong ... |
PMC6920765 | core_pubmed_pmc | Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months? | Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months? Abstract Mitotane is the most effective agent in post-operative treatment of adrenocortical carcinoma. In adults, the starting dose is 2–3 g/... |
PMC9144775 | core_pubmed_pmc | Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations | Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations Abstract Malaria is a severe parasite infectious disease with high fatality. As one of the approved treatments of this disease, hydroxychloroquine (HCQ) lacks clinica... |
PMC7994227 | core_pubmed_pmc | Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies | Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies Abstract Background Magnesium ions (Mg 2+ ) increase and prolong opioid analgesia in chronic and acute pain. The nature of this synergistic analgesic interaction has not ye... |
PMC8048549 | core_pubmed_pmc | Prediction of Fracture Risk From Early‐Stage Bone Markers in Patients With Osteoporosis Treated With Once‐Yearly Administered Zoledronic Acid | Prediction of Fracture Risk From Early‐Stage Bone Markers in Patients With Osteoporosis Treated With Once‐Yearly Administered Zoledronic Acid Abstract Abstract The prevention of fractures is the ultimate goal of osteoporosis treatments. To achieve this objective, developing a method to predict fracture risk in the earl... |
PMC12765438 | core_pubmed_pmc | Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer's disease | Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer's disease Abstract Abstract Erythropoietin (EPO) shows promise for Alzheimer's disease (AD) but has poor brain penetration, necessitating high doses that cause hematopoietic side effects. To improve brain delivery... |
PMC9297210 | core_pubmed_pmc | Potential new fluoroquinolone treatments for suspected bacterial keratitis | Potential new fluoroquinolone treatments for suspected bacterial keratitis Abstract Abstract Topical fluoroquinolones (FQs) are an established treatment for suspected microbial keratitis. An increased FQ resistance in some classes of bacterial pathogens is a concern. Some recently developed FQs have an extended spectru... |
PMC9322514 | core_pubmed_pmc | A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling | A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling Abstract Abstract The antihypertensive felodipine is a calcium channel blocker of the dihydropyridine type, and its pharmacodynamic effect directly correlates with its plasma concentra... |
PMC11139746 | core_pubmed_pmc | Combined whole-body dynamic and static PET/CT with low-dose [ 18 F]PSMA-1007 in prostate cancer patients | Combined whole-body dynamic and static PET/CT with low-dose [ 18 F]PSMA-1007 in prostate cancer patients Abstract Abstract Aim In addition to significant improvements in sensitivity and image quality, the recent introduction of long axial field-of-view (LAFOV) PET/CT scanners has enabled dynamic whole-body imaging for ... |
PMC11822664 | core_pubmed_pmc | First‐In‐Human Dose Finding Study of Venadaparib ( IDX ‐1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors | First‐In‐Human Dose Finding Study of Venadaparib ( IDX ‐1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors Abstract ABSTRACT Background Venadaparib, a novel poly (ADP‐ribose) polymerase (PARP) inhibitor, has demonstrated high PARP‐1/2 selectivity over other PARP family members and exhi... |
PMC11181028 | core_pubmed_pmc | 3D computer modeling of inhibitors targeting the MCF-7 breast cancer cell line | 3D computer modeling of inhibitors targeting the MCF-7 breast cancer cell line Abstract Abstract This study focused on developing new inhibitors for the MCF-7 cell line to contribute to our understanding of breast cancer biology and various experimental techniques. 3D QSAR modeling was used to design new tetrahydrobenz... |
PMC9546385 | core_pubmed_pmc | The [ 13 C ]octanoic acid breath test for gastric emptying quantification: A focus on nutrition and modeling | The [ 13 C ]octanoic acid breath test for gastric emptying quantification: A focus on nutrition and modeling Abstract Abstract Gastric emptying (GE) is the process of food being processed by the stomach and delivered to the small intestine where nutrients such as lipids are absorbed into the blood circulation. The comb... |
PMC12853688 | core_pubmed_pmc | The NewroBus platform: engineered humanized anti-TfR1 nanobodies for efficient brain delivery | The NewroBus platform: engineered humanized anti-TfR1 nanobodies for efficient brain delivery Abstract Background Delivery of biologic therapeutics to the central nervous system (CNS) is hindered by the blood–brain barrier (BBB), which restricts large molecule passage. Receptor-mediated transcytosis via transferrin rec... |
PMC10892260 | core_pubmed_pmc | Nanoparticles of Thiolated Xanthan Gum for the Oral Delivery of Miconazole Nitrate: In Vitro and In Vivo Evaluation | Nanoparticles of Thiolated Xanthan Gum for the Oral Delivery of Miconazole Nitrate: In Vitro and In Vivo Evaluation Abstract Abstract The objective of this research was to develop a mucoadhesive delivery system that improves permeation for the administration of poorly absorbed oral medications. Thiolation of xanthan gu... |
PMC4335132 | core_pubmed_pmc | Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Nebulized Sodium Nitrite (AIR001) Following Repeat-Dose Inhalation in Healthy Subjects | Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Nebulized Sodium Nitrite (AIR001) Following Repeat-Dose Inhalation in Healthy Subjects Abstract Introduction The efficacy of nebulized sodium nitrite (AIR001) has been demonstrated in animal models of pulmonary arterial hypertension (PAH), but it was not k... |
PMC12649081 | core_pubmed_pmc | Characterization of intramuscular Isoflupredone acetate in horses: pharmacokinetics and effects on anti-inflammatory mediators and plasma electrolytes | Characterization of intramuscular Isoflupredone acetate in horses: pharmacokinetics and effects on anti-inflammatory mediators and plasma electrolytes Abstract Abstract Background Corticosteroids, such as isoflupredone, are effective anti-inflammatory medications and as such are commonly used to treat inflammation asso... |
PMC7066310 | core_pubmed_pmc | The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor | The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor Abstract Abstract Background Dotinurad, a novel selective urate reabsorption inhibitor (SURI), increases... |
PMC12142322 | core_pubmed_pmc | Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative p -furoylamphenmulin against Mycoplasma gallisepticum in vivo in chickens | Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative p -furoylamphenmulin against Mycoplasma gallisepticum in vivo in chickens Abstract Abstract Mycoplasma gallisepticum ( M. gallisepticum , MG ) is the primary pathogen of chronic respiratory disease ( CRD ) in chickens and leads to pneumoni... |
PMC11011119 | core_pubmed_pmc | Stereoselective Pharmacokinetics of Ketamine Administered at a Low Dose in Awake Dogs | Stereoselective Pharmacokinetics of Ketamine Administered at a Low Dose in Awake Dogs Abstract Abstract Simple Summary Ketamine is commonly recommended as an adjunct to analgesic drugs, particularly in the postoperative care of hospitalized patients. Utilizing low doses is advised to target antinociceptive concentratio... |
PMC9323574 | core_pubmed_pmc | In Vitro Anatomical Models for Nasal Drug Delivery | In Vitro Anatomical Models for Nasal Drug Delivery Abstract Abstract Nasal drug delivery has been utilized for locally acting diseases for decades. The nose is also a portal to the systemic circulation and central nervous system (CNS). In the age of SARS-CoV2, the development of nasal sprays for vaccination and prophyl... |
PMC8664201 | core_pubmed_pmc | Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study | Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study Abstract Abstract Computer aided toxicity and pharmacokinetic prediction studies attracted the attention of pharmaceutical industries as an alternative means to predict potential drug candidates. In the present study, in-sili... |
PMC9314283 | core_pubmed_pmc | Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom? | Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom? Abstract Modeling and simulation emerges as a fundamental asset of drug development. Mechanistic modeling builds upon its... |
PMC7076505 | core_pubmed_pmc | Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery | Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery Abstract The retinal pigment epithelial (RPE) cell monolayer forms the outer blood–retinal barrier and has a crucial role in ocular pharmacokinetics. Although several RPE cell models are avail... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.